Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity

Acta Pharmacologica Sinica

Volumn 27, Issue 11, 2006, Pages 1447-1452

  Sun, Chun Yan ^a   Hu, Yu ^a   Guo, Tao ^a   Wang, Hua Fang ^a   Zhang, Xiao Ping ^a   He, Wen Juan ^a   Tan, Hao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Invasion; Matrix metalloproteinase; Multiple myeloma; Proliferation; Resveratrol

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GELATINASE A; GELATINASE B; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; RESVERATROL; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL INVASION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; MULTIPLE MYELOMA; PROTEIN EXPRESSION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; PLANTS, MEDICINAL; POLYGONUM; PROTO-ONCOGENE PROTEINS C-BCL-2; STILBENES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33750341603     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00343.x     Document Type: Article

References (19)

1. Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol 1999; 36: 3-8.
2. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti Roti JL, et al. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett 2002; 175: 165-73.
3. Bhat KP, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 2001; 61: 6137-44.
4. Dorrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 2001; 61: 4731-9.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
6. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411-24.
7. Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, et al. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol 2004; 165: 869-78.
8. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-73.
9. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 1999; 25: 65-77.
10. Cao Y, Fu ZD, Wang F, Liu HY, Han R. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod Res 2005; 7: 205-13.
11. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004; 10: 2190-202.
12. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001; 22: 1111-7.
13. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004; 3: 71-84.
14. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203-20.
15. Vacca A, Ribatti D, Presta M, Minischetti M, , Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-73.
16. Vacca A, Ribatti D, Iuriaro M, Albini A, Minischetti M, Bussolino F, et al. Human lymphoblastoid cells produces extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res 1998; 28: 55-68.
17. Narla RK, Dong Y, Klis DT, TUckun FM. Bis(4,7-dimethyl-1,10- phenanthroline) sulfatooxovanadium(IV) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin Cancer Res 2001; 7: 1094-101.
18. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 302: 369-73.
19. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi P, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495-504.